SpectraWAVE Appoints Brad Davis as Chief Commercial Officer and Bill Kelly as Chief Financial Officer

-- Experienced medical device executives Davis and Kelly to lead commercialization and finance during transformational growth phase --

BEDFORD, Mass.--(BUSINESS WIRE)--SpectraWAVE, Inc., a medical imaging company focused on improving the treatment and outcomes for patients with coronary artery disease (CAD), today announced the addition of two seasoned executives to its leadership team. Brad Davis has been named Chief Commercial Officer (CCO), and Bill Kelly has been named Chief Financial Officer (CFO).

“The addition of these exceptional leaders to our team represents an exciting inflection point for SpectraWAVE as we enter the new year,” said Eman Namati, Ph.D., Chief Executive Officer of SpectraWAVE. “The response to our recently launched HyperVue Imaging System for optimizing coronary stenting procedures in the catheterization lab has been tremendous. As we plan to expand our commercial footprint and product portfolio, bringing Brad and Bill onto the team is a vital step towards ensuring our success. Their combined expertise in commercialization and financial management will be instrumental in advancing our mission to improve patient outcomes, empower physicians, and create long-term value for our shareholders, building on the momentum of our $50M Series B funding.”

As Chief Commercial Officer, Brad will lead global strategy and commercialization efforts at SpectraWAVE. He brings over 24 years of experience in cardiovascular medical devices, having worked for both large and small companies, including Guidant, Boston Scientific and CSI. Most recently, Brad was CCO at OpSens, where he led the scale-up of a similarly sized commercial team and rapidly grew the business, successfully culminating in an acquisition by Haemonetics. “I am thrilled to join SpectraWAVE at such a pivotal moment in its journey,” said Davis. “The newly launched HyperVue Imaging System provides incredible value to patients, and will serve as a central hub in the cath lab for future enhancements, allowing us to further partner with customers and significantly improve outcomes for patients with coronary artery disease.”

Bill Kelly, newly appointed Chief Financial Officer, will lead SpectraWAVE’s financial strategy, investor relations, and operational efficiency. He joins SpectraWAVE from Vicarious Surgical, where he served as CFO and successfully took the company public, raising over $275 million through initial and follow-on public offerings. Prior to his tenure at Vicarious Surgical, Bill was CFO at Exosome Diagnostics, where he played an instrumental role in raising capital and launching commercial operations, ultimately leading to the company’s acquisition by BioTechne. “SpectraWAVE has built a powerful imaging platform in a critical area of healthcare – management of coronary artery disease,” noted Kelly. “I’m excited to join the team during an exciting period of growth and collaborate across the organization to ensure we have the resources and infrastructure to meet our short- and long-term objectives.”

Intravascular imaging is an essential tool to optimize coronary stenting procedures, providing key insights into plaque morphology, plaque modification decisions, stent and balloon sizing and landing zone selection, confirmation of treatment optimization, and future adverse event risk. Prior intravascular imaging technologies offer compromises in image resolution, image depth, and ease of use. HyperVue^TM is the first intravascular imaging technology to combine two important imaging technologies, DeepOCT and NIRS, while optimizing for image quality and procedural efficiency in the cath lab, including no-flush catheter prep, fast and long pullbacks designed to reduce and remove the use of contrast, and the most comprehensive AI-driven workflow and image analysis offering.

About SpectraWAVE, Inc.

SpectraWAVE, located in Bedford, Mass., is a privately held medical device company founded in 2017 to provide unrivaled optical and computational insights to improve the treatment and outcomes for patients with coronary artery disease (CAD). CAD, the buildup of plaque in the wall of the arteries that supply blood to the heart, affects 20.5 million adults aged 20 and older. In CAD patients that undergo percutaneous stent placement, it is estimated that one in five patients experience adverse events within two years. SpectraWAVE’s flagship HyperVue^TM Imaging System combines next generation DeepOCT^TM images and near infrared spectroscopy (NIRS) with workflows optimized for the cardiac catheterization lab, and serves as a central hub for future enhancements that will continue to empower interventionalists in their treatment decision making and optimization. The HyperVue Imaging System is intended for the imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. The NIRS capability of the system is intended for the identification of patients and plaques at increased risk of major adverse cardiac events. For more information and complete indications for use, please visit www.spectrawave.com.

HyperVue, Starlight, and DeepOCT are commercial trademarks cleared for sale in the U.S.A.